Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results matching your filters

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaRecruiting
NCT07144163Phase 3Updated Aug 12, 2026
Sponsor: Crinetics Pharmaceuticals Inc.
Congenital Adrenal Hyperplasia · Classic Congenital Adrenal Hyperplasia
United States, Argentina, Australia, Austria, Brazil +9 more
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat AllergyRecruiting
NCT07675811Phase 3Updated Aug 12, 2026
Sponsor: Regeneron Pharmaceuticals
Allergic Conjunctivitis
United States
Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaRecruiting
NCT06822790Phase 3Updated Aug 12, 2026
Sponsor: Arrowhead Pharmaceuticals
Hypertriglyceridemia
United States, Argentina, Australia, Belgium, Brazil +18 more
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderRecruiting
NCT07759128Phase 3Updated Aug 12, 2026
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
United States
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesRecruiting
NCT07102628Phase 3Updated Aug 12, 2026
Sponsor: Novartis Pharmaceuticals
Acute Coronary Syndrome
Argentina, Australia, Canada, China, France +9 more
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)Recruiting
NCT07555483Phase 3Updated Aug 11, 2026
Sponsor: Grifols Therapeutics LLC
Alpha 1 Antitrypsin Deficiency
United States, Denmark, Germany, Ireland, Netherlands +4 more
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Recruiting
NCT05005975Phase 3Updated Aug 11, 2026
Sponsor: Tanabe Pharma America, Inc.
EPP · XLP
United States, Australia, Bulgaria, Canada, Czechia +10 more
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Recruiting
NCT07011732Phase 3Updated Aug 11, 2026
Sponsor: Bristol-Myers Squibb
Alzheimer Disease
United States, Argentina, Brazil, Bulgaria, Canada +10 more
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruiting
NCT06051617Phase 3Updated Aug 11, 2026
Sponsor: Gilead Sciences
Primary Biliary Cholangitis
United States, Argentina, Australia, Austria, Belgium +24 more
The Many Roads to Trauma Recovery: A Clinical Trial Comparing Empirically Supported Treatments for Veterans With Co-Morbid Posttraumatic Stress and Substance Use Disorder SymptomsRecruiting
NCT07756723Phase 2, Phase 3Updated Aug 11, 2026
Sponsor: Coatesville VA Medical Center
Posttraumatic Stress Disorder (PTSD) · Substance Use Disorder (SUD)
United States
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruiting
NCT06979453Phase 3Updated Aug 11, 2026
Sponsor: Bristol-Myers Squibb
Plaque Psoriasis
United States, Argentina, Belgium, Brazil, Canada +11 more
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)Recruiting
NCT07753603Phase 3Updated Aug 11, 2026
Sponsor: Sling Therapeutics, Inc.
Thyroid Eye Disease, TED · Graves Orbitopathy
United States
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruiting
NCT07342478Phase 3Updated Aug 11, 2026
Sponsor: Newave Pharmaceutical Inc
CLL / SLL · CLL (Chronic Lymphocytic Leukemia) · CLL, Refractory · CLL, Relapsed
United States
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoRecruiting
NCT07682506Phase 3Updated Aug 11, 2026
Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
Vitiligo
China
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesRecruiting
NCT06671483Phase 3Updated Aug 11, 2026
Sponsor: Takeda
Psoriatic Arthritis
United States, Belgium, Bulgaria, Chile, Croatia +15 more
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Recruiting
NCT06911112Phase 3Updated Aug 11, 2026
Sponsor: Neurocrine Biosciences
Major Depressive Disorder
United States, Bulgaria, Lithuania, Romania, Slovakia
Uterus Transplantation to Treat InfertilityRecruiting
NCT05646992Phase 2, Phase 3Updated Aug 11, 2026
Sponsor: Johns Hopkins University
Uterine Factor Infertility
United States
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSRecruiting
NCT07322003Phase 3Updated Aug 11, 2026
Sponsor: Prilenia
Amyotrophic Lateral Sclerosis
United States, Belgium, Canada, France, Germany +8 more
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesRecruiting
NCT06671496Phase 3Updated Aug 11, 2026
Sponsor: Takeda
Psoriatic Arthritis
United States, Argentina, Australia, Brazil, Canada +7 more
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone MetastasesRecruiting
NCT06391242Phase 3Updated Aug 11, 2026
Sponsor: Canadian Cancer Trials Group
Cancer Metastatic
Canada
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruiting
NCT06918002Phase 3Updated Aug 11, 2026
Sponsor: Intergroupe Francophone du Myelome
Multiple Myeloma, Newly Diagnosed
France
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruiting
NCT05987241Phase 2, Phase 3Updated Aug 11, 2026
Sponsor: National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Renal Pelvis Urothelial Carcinoma · Muscle Invasive Ureter Urothelial Carcinoma · Muscle Invasive Urethral Urothelial Carcinoma
United States, Canada
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaRecruiting
NCT07100730Phase 3Updated Aug 11, 2026
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Neoplastic Disease · Glioblastoma · Glioblastoma (GBM) · Glioblastoma Multiform
Australia, Austria, Belgium, Netherlands
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruiting
NCT04708054Phase 2, Phase 3Updated Aug 11, 2026
Sponsor: M.D. Anderson Cancer Center
Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome
United States
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyRecruiting
NCT07479797Phase 3Updated Aug 11, 2026
Sponsor: Kite, A Gilead Company
Relapsed or Refractory Large B-cell Lymphoma
United States, Australia, Canada

Previous page Next page